BioCell Collagen II Study Results

NEWPORT BEACH, Calif.A multi-center, double-blind, placebo-controlled trial on the safety and efficacy of BioCell Collagen II in joint health has just been completed, showing positive results. The largest human study to date of joint conditions associated with osteoarthritis (OA), according to BioCell Technology LLC, the research involved BioCell Collagen II supplementation in subjects suffering from joint conditions associated with OA (osteoarthritis).  The results, including assessments by VAS and WOMAC scores, support the safety and efficacy of BioCell Collagen II in addressing the disease symptoms and in improving various physical activities.

 While a previous 16-patient study of the supplement demonstrated a similar safety profile and statistically significant efficacy in supporting chronic degenerative joint conditions in patients with OA, the current study enrolled 80 OA patients to strengthen the strengthen the findings. Also, the current trial featured a longer term than the prior study, enabling the use of various statistical analyses. Biocell noted one of the key findings from such analyses was a significant portion of OA patients experienced highly substantial improvement of their joint conditions. 

"Osteoarthritis is a degenerative joint condition that causes pain and inflammation.  It affects over 33 million Americans and is the most common joint disease," said Dr. Joosang Park, vice president of scientific affairs at BioCell Technology.  "I am particularly excited about these findings because they confirm earlier studies and offers further support that BioCell Collagen II is a safe and effective alternative to prescription drug products.  Qualitative and quantitative outcomes from this study indicate improvement in pain, stiffness, mobility, and overall improvement in quality of life."

The company expects the study to be published in the near future. " We are pleased with the results of this study and look forward to presenting the full study results, said Suhail Ishaq, executive vice president of BioCell Technology.